GSK GAINS EXPANDED INDICATION FOR BEXXAR

GlaxoSmithKline (GSK) has received FDA approval to expand the use of its cancer drug Bexxar to patients with non-Hodgkin's lymphoma (NHL).

The FDA-approved supplemental biologics license application allows GSK to market Bexxar (tositumomab and iodine I 131 tositumomab) for treatment of patients with CD 20 antigen expressing relapsed or refractory, low-grade, follicular, or transformed NHL, including patients with rituximab-refractory NHL.

The drug's original indication specified that patients must be refractory to rituximab and have relapsed following chemotherapy.